# US 2026/0083727 A1 · Pharmaceutical formulations of nintedanib for intraocular use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083727 A1
- Document ID: US20260083727A1
- Status: Published application
- Kind: A1
- Application number: 19/103,409
- Filed: 2023-08-11
- Published: 2026-03-26
- Earliest claimed: 2022-08-16
- Assignees: Boehringer Ingelheim International GmbH
- Applicants: Boehringer Ingelheim International GmbH
- Inventors: Paul ASHTON; Jianbing CHEN; Florian Andreas COLBATZKY; Hong GUO; Laibin LUO; Kerstin Julia SCHAEFER
- Web page: https://patentgrep.com/patent/US20260083727A1

## CPC

- A61K 9/0051: {Ocular inserts or implants}
- A61F 9/0017: {implantable in, or in contact with, the eye, e.g. ocular inserts}
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61P 27/02: Ophthalmic agents
- A61F 2240/001: Designing or manufacturing processes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Formulations and intravitreal implants containing nintedanib can be used in methods for the treatment of back-of-the-eye diseases.

## Claims

### Claim 1

A long-term sustained-release pharmaceutical formulation of the API comprising 80 to 95% (w/w) of API and 5 to 20% (w/w) of poly polyvinyl alcohol (PVA).

### Claim 2 (depends on 1)

The pharmaceutical formulation according to claim 1, wherein the formulation consists of 80 to 95% (w/w) of API, 5 to 20% (w/w) of PVA (w/w) and optionally traces of water.

### Claim 3 (depends on 1)

The pharmaceutical formulation according to claim 1, wherein the API is a pharmaceutically acceptable nintedanib salt or a blend of a pharmaceutically nintedanib salt with nintedanib free base, wherein said pharmaceutically acceptable nintedanib salt is nintedanib esylate, with a particle size distribution of D50≤20 μm and D90≤50 μm.

### Claim 4 (depends on 1)

The pharmaceutical formulation according to claim 1, wherein the PVA is characterized by a high degree of hydrolysis (≥97%) and optionally by a viscosity of 23.8-32.2 mPa*s as determined for a 4% PVA aqueous solution.

### Claim 5 (depends on 1)

A coated or uncoated intravitreal (IVT) implant having a body consisting of a long-term sustained-release pharmaceutical formulation according to claim 1, the body optionally having a polymer coating.

### Claim 6 (depends on 5)

The IVT implant according to claim 5, wherein the implant is cylindrical in shape, 0.2-0.4 mm in diameter and not more than 7 mm in length.

### Claim 7 (depends on 5)

The IVT implant according to claim 5, wherein the implant is characterized by a nintedanib esylate content in the range from 400-600 μg and/or by an in vitro daily release of nintedanib esylate of not less than about 1.1 μg/day over 6 months.

### Claim 8 (depends on 1)

A method for the preparation of the pharmaceutical formulation according to claim 1, the method comprising the steps of
a) preparing an aqueous PVA solution, and
b) mixing the PVA solution with API powder.

### Claim 9 (depends on 8)

The method according to claim 8, wherein in step a) the PVA solution has a mass concentration of PVA between 8% and 15% (w/v) and/or in step b) the ratio of PVA solution to API powder is about 1:1 (w/v).

### Claim 10 (depends on 5, 8)

A method for the preparation of the IVT implant according to claim 5, the method comprising the steps of
preparing a pharmaceutical formulation according to steps a) and b) of claim 8,
c) loading the pharmaceutical formulation into an extrusion device,
d) extruding the pharmaceutical formulation through an extruder head to form an extrudate strand,
e) optionally allowing the extrudate strand to dry,
f) heating the extrudate strand,
g) cutting the extrudate strand into implant pieces of identical lengths, and
h) sterilizing the implant pieces so obtained,
wherein the method may further comprise an optional step of coating the extrudate strand after step d), e), or f) or the implant pieces after step g) in a solution of coating polymer.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the extruder head has a circular profile and its inner diameter is not more than about 0.4 mm.

### Claim 12 (depends on 10)

The method according to claim 10, wherein in optional step e) the extrudate strand is allowed to dry at ambient temperature for at least two hours and/or in step f) the extrudate strand is heated for at least 2 hours to temperatures between 120° C. and 180° C.

### Claim 13 (depends on 1, 5)

A method for the treatment of a back-of-the-eye disease in a patient in need thereof, the method being characterized in that a pharmaceutical formulation according to claim 1 is administered to the eye of the patient, and wherein at least one IVT implant according to claim 5 is implanted into the vitreous of the eye of the patient.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the back-of-the-eye disease is selected from the group consisting of wet age-related macular degeneration (wAMD), dry macular degeneration, geographic atrophy, diabetic macular edema (DME), nonproliferative diabetic retinopathy (NPDR), cystoid macular edema (CME), choroidal neovascularization (CNV), retinal vein occlusion, and retinitis pigmentosa.

### Claim 15 (depends on 13, 14)

The method according to one or more of claims 13-14, wherein the method comprises repeated implantation of one IVT implant using a 24-gauge extra-thin wall needle, and the time interval between repeated implantations is at least 9 months.
